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Abstract The Kolmogorov-Arnold stochasticity parameter technique is
applied for the first time to the study of cancer genome sequencing, to reveal
mutations. Using data generated by next generation sequencing technologies,
we have analyzed the exome sequences of brain tumor patients with matched
tumor and normal blood. We show that mutations contained in sequencing
data can be revealed using this technique thus providing a new methodology
for determining subsequences of given length containing mutations i.e. its
value differs from those of subsequences without mutations. A potential
application for this technique involves simplifying the procedure of finding
segments with mutations, speeding up genomic research, and accelerating its
implementation in clinical diagnostic. Moreover, the prediction of a mutation
associated to a family of frequent mutations in numerous types of cancers
based purely on the value of the Kolmogorov function, indicates that this
applied marker may recognize genomic sequences that are in extremely low
abundance and can be used in revealing new types of mutations.
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1 Introduction
To study mutations in the genomic sequences of cancerous tissues we use
the statistic introduced initially by Kolmogorov [5] and later developed by
Arnold [6],[7] in defining a degree of randomness (stochasticity) for a given
sequence of real numbers. The universality of the method has been revealed
at measuring the degree of randomness of finite sequences in theory of dy-
namical systems and in number theory [6]. This approach has been applied
to physical problems, i.e. at the study of non-Gaussianities in cosmic mi-
crowave background radiation [8],[9],[10], of X-ray galaxy clusters [11]. This
method was instrumental in detecting the thermal trust effect (Yarkovsky-
Rubincam effect) for the first time in the properties of satellites probing
General Relativity [12].
2 Method
Let us briefly introduce the technique and the descriptors which were then
applied to the genomic data. For {X1, X2, . . . , Xn} n independent real-valued
variable ordered in increasing manner X1 ≤ X2 ≤ · · · ≤ Xn the cumulative
distribution function (CDF) is defined as F (x) = P{X ≤ x} [5],[6],[7].
The empirical distribution function Fn(x) will be
Fn(x) =

0 , x < X1 ;
k/n , Xk ≤ x < Xk+1, k = 1, 2, . . . , n− 1 ;
1 , Xn ≤ x .
Then the stochasticity parameter is defined as
λn =
√
n sup
x
|Fn(x)− F (x)| . (1)
Kolmogorov’s theorem [5] states that for any continuous CDF F the follow-
ing limit is converged uniformly
lim
n→∞
P{λn ≤ λ} = Φ(λ) , (2)
where the Φ(0) = 0,
Φ(λ) =
+∞∑
k=−∞
(−1)k e−2k2λ2 , λ > 0 , (3)
2
and the distribution (Kolmogorov’s) Φ is independent on F . For small values
of λ the following approximation yields
Φ(λ) ≈
√
2pi
λ
e−
pi2
8λ2 . (4)
This method thus provides the measure of the degree of randomness
(stochasticity) for sequences of n values within the interval of λn [0.3, 2.4]
[6],[7], see also [13].
3 Data
The following data have been used for the analysis. Gliomas are the most
frequent malignant tumors of the CNS and are defined by WHO grade I to
grade IV classification standards and histopathological features [14],[15]. Ap-
plication of novel techniques to elucidate the fundamental genetic mutations
in Grade II-III astroctyomas and Grade IV glioblastomas is a critical next
step in glioma research. Here, we interrogated exome data of 30 brain tumor
patients from the Preston Robert Tisch Brain Tumor Center at Duke Uni-
versity as described previously [3]. The exomes of 30 patients were selected
as they provided a large enough dataset to conduct our initial analysis. Each
case contained four datasets corresponding to aligned paired end sequencing
data files (both a forward and reverse file for each patients tumor and nor-
mal blood). Included in this study were 15 grade III astrocytomas and 15
grade IV glioblastoma. Samples on average yielded 36 and 32 somatic mu-
tations for grade III astrocytomas and grade IV glioblastoma, respectively.
Of particular interest to the general cancer community is the prevalence of
highly recurrent mutations across all types of cancer. To this end, a list of
highly recurrent mutations occurring in 23 genes commonly seen in cancer
was used to interrogate the dataset (Table 1). The selected genes are from
a list of frequently mutated genes in cancer provided by Personal Genome
Diagnostics (Baltimore, MD). Next, we surveyed the exome data to identify
any occurrence of these 407 highly recurrent mutations located within these
23 commonly mutated genes, see [16].
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Gene Gene Transcript
Symbol Description Accession
ABL1 c-abl oncogene 1; non-receptor tyrosine kinase X16416
AKT1 v-akt murine thymoma viral oncogene homolog 1 ENST00000349310
AKT2 v-akt murine thymoma viral oncogene homolog 2 NM 001626.3
ALK anaplastic lymphoma receptor tyrosine kinase NM 004304
BRAF v-raf murine sarcoma viral oncogene homolog B1 NM 004333
CDK4 cyclin-dependent kinase 4 NM 000075.2
EGFR epidermal growth factor receptor NM 005228
ERBB2 v-erb-b2 erythroblastic leukemia viral
oncogene homolog 2 NM 004448
FGFR1 fibroblast growth factor receptor 1 NM 023110
FGFR3 fibroblast growth factor receptor 3 NM 000142
FLT3 fms-related tyrosine kinase 3 NM 004119
HRAS v-Ha-ras Harvey rat sarcoma viral
oncogene homolog NM 005343
IDH1 isocitrate dehydrogenase 1 (NADP+); soluble NM 005896.2
IDH2 isocitrate dehydrogenase 2 (NADP+); mitochondrial NM 002168.2
JAK2 Janus kinase 2 ENST00000381652
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homolog NM 000222
KRAS v-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog NM 004985
MET met proto-oncogene (hepatocyte growth )
factor receptor) NM 000245
MET met proto-oncogene (hepatocyte growth
factor receptor) NM 001127500
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog NM 002524
PDGFRa platelet-derived growth factor receptor;
alpha polypeptide NM 006206
PIK3CA phosphoinositide-3-kinase; catalytic;
alpha polypeptide NM 006218.1
RET ret proto-oncogene NM 020975
Table 1: 23 genes commonly mutated in cancer.
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4 Analysis
The data for 30 patients have been analysed in the following manner. First,
for each dataset the cumulative distribution function has been obtained
for 3-combinations of nucleotides (guanine, adenine, thymine, and cytosine
(G,A,T,C) i.e. of codons. For comparison, in one and two-based analysis of
the same data, no CDF was possible to define due to large scatter in the fre-
quency counts, however it was possible for the 3-base empirical distribution
for each particular genomic sequence, followed by obtaining of the stochas-
ticity parameter and then the Kolmogorov’s function Φ. The fact that Φ
was possible to define only for 3-base CDF can be considered as a genuine
feature linked to the nature of the genetic coding (first noticed by cosmolo-
gist George Gamow in 1950s) determined by the chemical properties of the
molecules forming the nucleotides.
The above described exome data were represented in a format of over 50
mln rows, of 100-base each, i.e. total in about 109-valued sequences. We
analysed such datasets for 30 patients, a block of 4 datasets, representing
paired-end sequencing, was available for each patient, including those for
blood and tumor, denoted as normal and with tumor, respectively. The
following aim was inquired into: whether the K-A technique is able to dis-
tinguish the strings i.e. sequence pieces of given length, with and without
mutations, for a given sample of mutations. Figure 1 represents the results
for computations for 100-base rows containing such mutations in all 119
blocks (dark column in the right; 1 file was corrupted), and the mean of the
function Φ for 50 rows without mutations (light-colored column in the left)
in the same sequence where the former mutations have been located. The
same procedure has been repeated for shorter i.e. for 50 and 25-base strings
with and without mutations (the right two double-columns, respectively).
The shorter, 50-base strings were generated in the following manner: if the
mutation is located completely either in the first or the second half of the
100-base string, then the corresponding halves were included in the analysis.
In the case of partial location, the proper number of bases was included from
either side, the mutations are included completely even at partly passage to
the next row. Similar was the case for 25-base strings, while for no-mutation
strings (rows) their initial 50 or 25-base parts were included in the analysis.
For no-mutation rows their alignment i.e. their position in the sequence was
not important. The error bars correspond to standard errors. The analy-
sis was performed by means of a software created in Pascal in environment
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Delphi and intended to be made public in due course. The CPU time for
one sequence (about 109 nucleotides) is about 1 hour for i7, 2600 3.4 GHz
processor of 6GB memory.
Figure 1: The function Φ averaged for rows with mutations (dark bars) and
normal ones (light bars) averaged over 50 rows, for 100, 50 and 25-base rows
(here denoted as word), correspondingly. Error bars correspond to standard
errors.
Then, rows containing the most frequent specific mutations in the same
dataset of 30 patients (Table 2), have been analysed. Obviously, more fre-
quent mutations provide higher statistics, and Table 2 and Figure 2 are repre-
sented to show the scales of the input frequency numbers vs the results. The
mutations i.e. the genes and the mutant positions and amino acid changes
are known for the codes listed in Table 2, and from the individual muta-
tion reports of the performed studies [3] one can list all mutations contained
within each tumor; we intend to address these issues in next publications
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Table 2: The codes (MC) and frequency counts for 7 highest recurrent mu-
tations in the studied database.
N MC Frequency
1 AAAGANAAATT 3032
2 CATCTNAAAAA 2569
3 AGAAGNAAAAA 2427
4 ATTTTNTCTTT 2409
5 TGCCCNGGCTG 2253
6 CTTTCNTTTCT 2200
7 TCTTCNTTTTT 2123
on the applications of method discussed here. The results for the mean Φ
with standard error bars are presented in Figure 2. One can see that certain
specific mutations can be distinguished by the value of mean Φ.
5 One step further: possibility for discover-
ing new mutations
Up to now we were estimating the Kolmogorov function Φ for genomic se-
quence pieces (rows) with known mutations and without (of those) mutations.
We reveal the differences in the mean values of Φ for rows with and without
those mutations. If so, then one can pose the inverse problem, namely, can
one try to detect unknown mutations based on the value of Φ, if estimated
blindly in a given genome sequence. In Table 4 we show the results for a
sample from the above studied database from genome with tumor (081T1):
11 rows (of over 50 mln) with Φ > 0.7 (only the rows with the number of
unidentified nucleodites N ≤ 3 have been taken into account), have been
revealed with the codes given in the Table 3 as candidates for mutations.
Obviously, certain part of these cases can be just noise, i.e. without any as-
sociation to real mutations, however, if at least part of these list when studied
by conventional methods will be confirmed as associated to mutations, then
one will have an explicit tool for detection of unknown mutations by means of
this relatively simple, i.e. of small time and manpower consuming method.
Certainly, the exhausting answer to this question will need comprehensive
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Figure 2: The same as in Figure 1, but with the averaged values of the
function Φ for 100-base rows for the highest recurrent specific mutations in
the studied dataset as listed in Table 2.
parallel studies with different analysis methods. However, for now, for il-
lustration, for the given sample of detected candidates for mutations, we
performed the following. We have sampled five reads from the aforemen-
tioned list of 11 rows in Table 3 and aligned them to the human genome for
further investigation. While none of these five reads matched to previously
reported mutations in the COSMIC database, one of the reads aligned to a
region of interest for oncogenomic laboratories. This read aligned to the tran-
scriptional regulator ARID1A, a SWI/SNF family member that is frequently
mutated in numerous types of cancers, including gastric, ovarian, and pan-
creatic cancers [17],[18],[19],[20]. Probability for a chance coincidence is less
than 10−5 (assuming for simplicity an equipartition in the frequency counts,
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Table 3: The codes for candidates for mutations in a genome sequence with
high Φ at given row numbers.
Line N MC
1186009 TTGTGNAAGGG
4073568 CCACGNCCTGG
11648505 ATACANAACGC
21240249 AAGGANACTGA
21827969 CAATTNGGGAA
33372865 GCCGGNCGCGG
34549019 TGGCCNAGAAG
36995074 TGAAGNGTTCT
42622891 TTGTTNTTTTA
43978737 AGAAANATATT
50647272 TGACTNAAAGG
cf. Table 2), thus proving the efficiency of the method for blind application
to detasets using the prviously calibrated Φ.
Another potential application for this technique involves detection of rare
variants of sequencing data, where the parameter Φ may recognize genomic
sequences that are in extremely low abundance and warrant further investi-
gation by the researchers.
6 Conclusions
The following basic conclusions can be drawn from the above analysis:
(a) the stability of the descriptor, that is small standard errors and hence
high and stable confidence level of the values of Φ for paired-end sequence
rows both for normal, i.e. without mutations, and those with mutations;
(b) the difference in values of Φ for rows with and without mutations;
(c) the considered variations of string lengths still reflect the tendency;
(d) rows with certain mutations can be distinguished by means of the
used marker.
The presented results demonstrate for the greater cancer research com-
munity the power of the Kolmogorov-Arnold technique for identification of
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mutations in paired-end genome sequencing data. In addition to the signifi-
cance of revealing the important nature of the difference in the degree of the
randomness between the genome sequence with and without mutations, the
method also has an important application potential. It may be applied to
non aligned sequencing segments, which may significantly simplify procedure
of finding segments with mutations and could speed up genomic research and
its implementation in clinical diagnostic.
Finally, the consideration of the inverse problem, namely, the revealing of
a mutation associated to a tumour based purely on the computation of the
value of the marker when blinded to the data, indicates that the latter may
be used for detection of rare or new types of mutations.
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